299 related articles for article (PubMed ID: 17727729)
1. Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity.
Goila-Gaur R; Khan MA; Miyagi E; Kao S; Strebel K
Retrovirology; 2007 Aug; 4():61. PubMed ID: 17727729
[TBL] [Abstract][Full Text] [Related]
2. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
Binka M; Ooms M; Steward M; Simon V
J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
[TBL] [Abstract][Full Text] [Related]
3. Vpr.A3A chimera inhibits HIV replication.
Aguiar RS; Lovsin N; Tanuri A; Peterlin BM
J Biol Chem; 2008 Feb; 283(5):2518-25. PubMed ID: 18057006
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
[TBL] [Abstract][Full Text] [Related]
5. Functional domain organization of human APOBEC3G.
Gooch BD; Cullen BR
Virology; 2008 Sep; 379(1):118-24. PubMed ID: 18639915
[TBL] [Abstract][Full Text] [Related]
6. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
7. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization.
Dang Y; Wang X; Zhou T; York IA; Zheng YH
J Virol; 2009 Sep; 83(17):8544-52. PubMed ID: 19535447
[TBL] [Abstract][Full Text] [Related]
9. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
Ao Z; Yu Z; Wang L; Zheng Y; Yao X
PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
[TBL] [Abstract][Full Text] [Related]
10. APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner.
Bandarra S; Miyagi E; Ribeiro AC; Gonçalves J; Strebel K; Barahona I
J Virol; 2021 Nov; 95(23):e0117021. PubMed ID: 34523960
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif.
Shirakawa K; Takaori-Kondo A; Yokoyama M; Izumi T; Matsui M; Io K; Sato T; Sato H; Uchiyama T
Nat Struct Mol Biol; 2008 Nov; 15(11):1184-91. PubMed ID: 18836454
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-fusion as a strategy to modulate protein half-life: A3G antiviral activity revisited.
Cadima-Couto I; Freitas-Vieira A; Nowarski R; Britan-Rosich E; Kotler M; Goncalves J
Virology; 2009 Oct; 393(2):286-94. PubMed ID: 19717177
[TBL] [Abstract][Full Text] [Related]
13. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
Rose KM; Marin M; Kozak SL; Kabat D
AIDS Res Hum Retroviruses; 2005 Jul; 21(7):611-9. PubMed ID: 16060832
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
[TBL] [Abstract][Full Text] [Related]
15. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
16. Determinants of FIV and HIV Vif sensitivity of feline APOBEC3 restriction factors.
Zhang Z; Gu Q; Jaguva Vasudevan AA; Hain A; Kloke BP; Hasheminasab S; Mulnaes D; Sato K; Cichutek K; Häussinger D; Bravo IG; Smits SH; Gohlke H; Münk C
Retrovirology; 2016 Jul; 13(1):46. PubMed ID: 27368163
[TBL] [Abstract][Full Text] [Related]
17. Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo.
Stavrou S; Crawford D; Blouch K; Browne EP; Kohli RM; Ross SR
PLoS Pathog; 2014 May; 10(5):e1004145. PubMed ID: 24851906
[TBL] [Abstract][Full Text] [Related]
18. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
Xu H; Chertova E; Chen J; Ott DE; Roser JD; Hu WS; Pathak VK
Virology; 2007 Apr; 360(2):247-56. PubMed ID: 17126871
[TBL] [Abstract][Full Text] [Related]
19. APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells.
Batisse J; Guerrero SX; Bernacchi S; Richert L; Godet J; Goldschmidt V; Mély Y; Marquet R; de Rocquigny H; Paillart JC
J Virol; 2013 Jun; 87(11):6492-506. PubMed ID: 23576497
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
Mbisa JL; Barr R; Thomas JA; Vandegraaff N; Dorweiler IJ; Svarovskaia ES; Brown WL; Mansky LM; Gorelick RJ; Harris RS; Engelman A; Pathak VK
J Virol; 2007 Jul; 81(13):7099-110. PubMed ID: 17428871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
